Nutritionally variant streptococci: Difference between revisions
From IDWiki
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 12: | Line 12: | ||
* [[Subacute bacterial endocarditis]] is the most well-known disease association |
* [[Subacute bacterial endocarditis]] is the most well-known disease association |
||
== Management == |
|||
* Susceptibilities shown below are from several studies[[CiteRef::kanamoto2018an]][[CiteRef::patel2017an]][[CiteRef::mushtaq2016di]] |
|||
{| class="wikitable" |
|||
!Antibiotic |
|||
![[Abiotrophia defectiva]] |
|||
![[Granulicatella adiacens]] |
|||
![[Granulicatella elegans]] |
|||
|- |
|||
|Penicillin |
|||
|14 to 57% |
|||
|34 to 82% |
|||
|80 to 100% |
|||
|- |
|||
|Ampicillin |
|||
|86% |
|||
|100% |
|||
|100% |
|||
|- |
|||
|Piperacillin |
|||
|0% |
|||
|53% |
|||
|100% |
|||
|- |
|||
|Cefazolin |
|||
|29% |
|||
|88% |
|||
|100% |
|||
|- |
|||
|Ceftriaxone |
|||
|92 to 100% |
|||
|22 to 76% |
|||
|90 to 100% |
|||
|- |
|||
|Ceftazidime |
|||
|0% |
|||
|0% |
|||
|50% |
|||
|- |
|||
|Imipenem |
|||
|100% |
|||
|100% |
|||
|100% |
|||
|- |
|||
|Meropenem |
|||
|72 to 81% |
|||
|87 to 95% |
|||
|91% |
|||
|- |
|||
|Gentamicin |
|||
|0% |
|||
|0% |
|||
|0% |
|||
|- |
|||
|Ciprofloxacin |
|||
|100% |
|||
|18% |
|||
|17% |
|||
|- |
|||
|Levofloxacin |
|||
|100% |
|||
|97 to 100% |
|||
|92% |
|||
|- |
|||
|Minocycline |
|||
|57% |
|||
|94% |
|||
|100% |
|||
|- |
|||
|Vancomycin |
|||
|100% |
|||
|100% |
|||
|83 to 100% |
|||
|- |
|||
|TMP-SMX |
|||
|14% |
|||
|0% |
|||
|17% |
|||
|} |
|||
[[Category:Gram-positive cocci]] |
[[Category:Gram-positive cocci]] |
||
Latest revision as of 19:28, 11 March 2022
Background
- Require pyridoxine (vitamin B6) supplementation to group
- Also called pyridoxal-dependent or stalliting streptococci
Organisms
Clinical Manifestations
- Subacute bacterial endocarditis is the most well-known disease association
Management
| Antibiotic | Abiotrophia defectiva | Granulicatella adiacens | Granulicatella elegans |
|---|---|---|---|
| Penicillin | 14 to 57% | 34 to 82% | 80 to 100% |
| Ampicillin | 86% | 100% | 100% |
| Piperacillin | 0% | 53% | 100% |
| Cefazolin | 29% | 88% | 100% |
| Ceftriaxone | 92 to 100% | 22 to 76% | 90 to 100% |
| Ceftazidime | 0% | 0% | 50% |
| Imipenem | 100% | 100% | 100% |
| Meropenem | 72 to 81% | 87 to 95% | 91% |
| Gentamicin | 0% | 0% | 0% |
| Ciprofloxacin | 100% | 18% | 17% |
| Levofloxacin | 100% | 97 to 100% | 92% |
| Minocycline | 57% | 94% | 100% |
| Vancomycin | 100% | 100% | 83 to 100% |
| TMP-SMX | 14% | 0% | 17% |
References
- ^ Taisei Kanamoto, Shigemi Terakubo, Hideki Nakashima. Antimicrobial Susceptibilities of Oral Isolates of Abiotrophia and Granulicatella According to the Consensus Guidelines for Fastidious Bacteria. Medicines. 2018;5(4):129. doi:10.3390/medicines5040129.
- ^ Kunatum Prasidthrathsint, Mark A. Fisher. Robin Patel. Antimicrobial Susceptibility Patterns among a Large, Nationwide Cohort of Abiotrophia and Granulicatella Clinical Isolates. Journal of Clinical Microbiology. 2017;55(4):1025-1031. doi:10.1128/jcm.02054-16.
- ^ Ammara Mushtaq, Kerryl E. Greenwood-Quaintance, Nicolynn C. Cole, Peggy C. Kohner, Sherry M. Ihde, Gregory J. Strand, Lance W. Harper, Abinash Virk, Robin Patel. Differential Antimicrobial Susceptibilities of Granulicatella adiacens and Abiotrophia defectiva. Antimicrobial Agents and Chemotherapy. 2016;60(8):5036-5039. doi:10.1128/aac.00485-16.
